InsiderTrades.com logo
James M. Frates net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

James Frates Biography and Net Worth

CFO of Amylyx Pharmaceuticals

Jim Frates serves as Amylyx’s Chief Financial Officer, having previously been the CFO of Alkermes for 22 years. Prior to working at Alkermes, Jim was a Vice President in the Life Sciences Practice at Robertson Stephens & Company. He currently serves on the board of directors of Sage Therapeutics and is a Trustee of St. Francis House, the largest homeless day shelter in Massachusetts. Jim earned a Bachelor of Arts in Government from Harvard College and a Master of Business Administration from the Harvard Graduate School of Business Administration.

What is James M. Frates' net worth?

The estimated net worth of James M. Frates is at least $4.06 million as of September 30th, 2025. Frates owns 280,430 shares of Amylyx Pharmaceuticals stock worth more than $4,063,431 as of December 5th. This net worth evaluation does not reflect any other investments that Frates may own. Additionally, Frates receives a salary of $763,160.00 as CFO at Amylyx Pharmaceuticals. Learn More about James M. Frates' net worth.

How old is James M. Frates?

Frates is currently 57 years old. There are 4 older executives and no younger executives at Amylyx Pharmaceuticals. The oldest executive at Amylyx Pharmaceuticals is Dr. Camille L. Bedrosian M.D., Chief Medical Officer, who is 71 years old. Learn More on James M. Frates' age.

What is James M. Frates' salary?

As the CFO of Amylyx Pharmaceuticals, Inc., Frates earns $763,160.00 per year. There are 2 executives that earn more than Frates. The highest earning executive at Amylyx Pharmaceuticals is Mr. Joshua B. Cohen, Co-Founder, Co-CEO & Director, who commands a salary of $1,080,000.00 per year. Learn More on James M. Frates' salary.

How do I contact James M. Frates?

The corporate mailing address for Frates and other Amylyx Pharmaceuticals executives is , , . Amylyx Pharmaceuticals can also be reached via phone at 617-682-0917 and via email at [email protected]. Learn More on James M. Frates' contact information.

Has James M. Frates been buying or selling shares of Amylyx Pharmaceuticals?

James M. Frates has not been actively trading shares of Amylyx Pharmaceuticals during the last ninety days. Most recently, James M. Frates sold 10,558 shares of the business's stock in a transaction on Tuesday, September 30th. The shares were sold at an average price of $14.65, for a transaction totalling $154,674.70. Following the completion of the sale, the chief financial officer now directly owns 280,430 shares of the company's stock, valued at $4,108,299.50. Learn More on James M. Frates' trading history.

Who are Amylyx Pharmaceuticals' active insiders?

Amylyx Pharmaceuticals' insider roster includes Camille Bedrosian (Insider), Joshua Cohen (Co-Founder), Joshua Cohen (CEO), James Frates (CFO), M Jr (Director), Justin Klee (CEO), Justin Klee (Co-Founder), Gina Mazzariello (Insider), Daphne Quimi (Director), Patrick Yeramian (Insider), and Bernhardt Zeiher (Director). Learn More on Amylyx Pharmaceuticals' active insiders.

Are insiders buying or selling shares of Amylyx Pharmaceuticals?

In the last year, Amylyx Pharmaceuticals insiders bought shares 1 times. They purchased a total of 10,000 shares worth more than $37,000.00. In the last year, insiders at the sold shares 13 times. They sold a total of 169,893 shares worth more than $1,666,686.16. The most recent insider tranaction occured on December, 1st when insider Camille L Bedrosian sold 6,580 shares worth more than $94,423.00. Insiders at Amylyx Pharmaceuticals own 12.3% of the company. Learn More about insider trades at Amylyx Pharmaceuticals.

Information on this page was last updated on 12/1/2025.

James M. Frates Insider Trading History at Amylyx Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/30/2025Sell10,558$14.65$154,674.70280,430View SEC Filing Icon  
3/31/2025Sell10,896$3.47$37,809.12290,988View SEC Filing Icon  
9/12/2024Buy40,000$2.53$101,200.00233,464View SEC Filing Icon  
3/5/2024Sell1,792$18.73$33,564.16134,784View SEC Filing Icon  
1/9/2024Sell2,716$16.33$44,352.28112,035View SEC Filing Icon  
5/16/2023Sell32,500$26.94$875,550.0055,676View SEC Filing Icon  
3/16/2023Sell32,500$31.89$1,036,425.001,509View SEC Filing Icon  
See Full Table

James M. Frates Buying and Selling Activity at Amylyx Pharmaceuticals

This chart shows James M Frates's buying and selling at Amylyx Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Amylyx Pharmaceuticals Company Overview

Amylyx Pharmaceuticals logo
Amylyx Pharmaceuticals, Inc., a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada. It is also developing AMX0114 for other neurodegenerative diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $14.49
Low: $13.91
High: $14.64

50 Day Range

MA: $14.00
Low: $12.18
High: $15.79

2 Week Range

Now: $14.49
Low: $2.60
High: $16.96

Volume

781,740 shs

Average Volume

1,403,731 shs

Market Capitalization

$1.59 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A